The Challenge of Genetic Variants of Uncertain Clinical Significance : A Narrative Review.
Wylie BurkeErik ParensWendy K ChungSara M BergerPaul S AppelbaumPublished in: Annals of internal medicine (2022)
Genomic tests expand diagnostic and screening opportunities but also identify genetic variants of uncertain clinical significance (VUSs). Only a minority of VUSs are likely to prove pathogenic when later reassessed, but resolution of the uncertainty is rarely timely. That uncertainty adds complexity to clinical decision making and can result in harms and costs to patients and the health care system, including the time-consuming analysis required to interpret a VUS and the potential for unnecessary treatment and adverse psychological effects. Current efforts to improve variant interpretation will help reduce the scope of the problem, but the high prevalence of rare and novel variants in the human genome points to VUSs as an ongoing challenge. Additional strategies can help mitigate the potential harms of VUSs, including testing protocols that limit identification or reporting of VUSs, subclassification of VUSs according to the likelihood of pathogenicity, routine family-based evaluation of variants, and enhanced counseling efforts. All involve tradeoffs, and the appropriate balance of measures is likely to vary for different test uses and clinical settings. Cross-specialty deliberation and public input could contribute to systematic and broadly supported policies for managing VUSs.
Keyphrases
- escherichia coli
- copy number
- decision making
- end stage renal disease
- endothelial cells
- newly diagnosed
- public health
- chronic kidney disease
- adverse drug
- mental health
- prognostic factors
- gene expression
- cystic fibrosis
- human health
- genome wide
- smoking cessation
- physical activity
- combination therapy
- pseudomonas aeruginosa
- candida albicans
- antiretroviral therapy
- replacement therapy
- hiv infected